elranatamab
pfizer
['magnetismm-3', 'mmsm', 'elranatamab']
elranatamab (magnetismm-3): 18% of pts enrolled in us were black (that's good). 52% with infections. 6% treated-related neuropathy (this was a concern earlier). 60.6% orr, crs 58.9%, icans 2.2% (no grade 3+). median f/u only 3.7 months. #asco22 #mmsm 
Assistant Professor at the University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma and MRD. COI: https://t.co/1DEICEb1Q7